Holen Sie sich die Stockscreener-App
13.29
1.78%
0.2558
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
Cash per share of Tonix Pharmaceuticals Holding Corp. – DUS:TPM0 - TradingView
Tonix Pharmaceuticals (TNXP) to Release Quarterly Earnings on Monday - MarketBeat
TD Cowen initiated coverage on Tonix Pharma with a new price target - Quantisnow
TD Cowen initiates Tonix Pharma stock with buy rating, $22 target - Investing.com India
Tonix Pharmaceuticals Holding (TNXP) price target decreased by 15.76% to 55.42 - MSN
Tonix Pharmaceuticals Holding Corp. Files Form 8-K Current Report with NASDAQ Listing Details (May 1, 2026) - Minichart
Tonix Pharmaceuticals (NASDAQ: TNXP) gives early look at Q1 2026 sales - Stock Titan
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
Tonix Pharmaceuticals (TNXP) Proxy filing Summary - Quartr
Tonix Pharmaceuticals (TNXP) Announces Phase 2 Study Plans for L - GuruFocus
Tonix plans Phase 2 Lyme disease prevention study in 2027 - Investing.com UK
Tonix plans Phase 2 Lyme disease prevention study in 2027 By Investing.com - Investing.com Australia
Tonix Pharma Advances TNX-4800 Lyme Disease Prevention Program - TipRanks
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symp - The Manila Times
Tonix (NASDAQ: TNXP) plans Phase 2 Lyme antibody study for 2027 - Stock Titan
A two-dose Lyme prevention antibody is planned for a U.S. field study - Stock Titan
Tonix Pharmaceuticals stock hits new 52-week low: What's driving the action? - MSN
Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’ - MSN
(TNXP) Risk Channels and Responsive Allocation - Stock Traders Daily
Tonix Pharmaceuticals Holding Corp (STU:TPM0) Stock Price & 30 Year Financial Data - GuruFocus
Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell - MarketBeat
Tonix Pharmaceuticals Showcases Promising Preclinical Immuno-Oncology Advances with TNX-1700 and TNX-4700 at AACR 2026 1 - Minichart
Tonix Pharma Highlights Preclinical Progress in Oncology Pipeline - TipRanks
Preclinical cancer data for Tonix (NASDAQ: TNXP) TNX-1700 and TNX-4700 - Stock Titan
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Yahoo Finance
Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
(TNXP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development - Sahm
Tonix publishes pharmacokinetic study on fibromyalgia drug By Investing.com - Investing.com Australia
Tonix Pharmaceuticals (TNXP) Reports Positive Findings on TNX-10 - GuruFocus
Tonix publishes pharmacokinetic study on fibromyalgia drug - Investing.com
Tonix Pharmaceuticals Announces Publication of Steady-State - GlobeNewswire
Analyst Upgrade: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear marketWeekly Earnings Recap & Reliable Price Breakout Alerts - baoquankhu1.vn
TNXP Options Volatility — NASDAQ:TNXP - TradingView — Track All Markets
TNXP Options Chain — NASDAQ:TNXP - TradingView
Profit Recap: Will Tonix Pharmaceuticals Holding Corp announce a stock split2026 Analyst Calls & Daily Chart Pattern Signals - baoquankhu1.vn
Will Tonix Pharmaceuticals Holding Corp stock benefit from M AInflation Watch & Daily Stock Trend Watchlist - baoquankhu1.vn
Why Tonix's External Atty Saw GC Role As A 'Natural Choice' - Law360
Liquidity Mapping Around (TNXP) Price Events - Stock Traders Daily
Tonix Pharmaceuticals Holding Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
1.94%
1.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):